147 related articles for article (PubMed ID: 38425459)
1. Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.
Konstantinopoulos PA; Xiong N; Krasner C; Liu JF; Sawyer H; Polak M; Needham H; Geddes M; Koppermann L; Shea M; Castro C; Cheng SC; Matulonis UA; Lee EK
Gynecol Oncol Rep; 2024 Apr; 52():101348. PubMed ID: 38425459
[TBL] [Abstract][Full Text] [Related]
2. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Konstantinopoulos PA; Lee EK; Xiong N; Krasner C; Campos S; Kolin DL; Liu JF; Horowitz N; Wright AA; Bouberhan S; Penson RT; Yeku O; Bowes B; Needham H; Hayes M; Sawyer H; Polak M; Shea M; Cheng SC; Castro C; Matulonis UA
J Clin Oncol; 2023 Jan; 41(3):599-608. PubMed ID: 36174113
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.
Chiorean EG; Picozzi V; Li CP; Peeters M; Maurel J; Singh J; Golan T; Blanc JF; Chapman SC; Hussain AM; Johnston EL; Hochster HS
Cancer Med; 2023 Oct; 12(20):20353-20364. PubMed ID: 37840530
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma.
Jia N; Che X; Jiang Y; Zhu M; Yang T; Feng W
Gynecol Oncol; 2021 Sep; 162(3):788-796. PubMed ID: 34183163
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
[TBL] [Abstract][Full Text] [Related]
7. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
Slomovitz BM; Filiaci VL; Walker JL; Taub MC; Finkelstein KA; Moroney JW; Fleury AC; Muller CY; Holman LL; Copeland LJ; Miller DS; Coleman RL
Gynecol Oncol; 2022 Mar; 164(3):481-491. PubMed ID: 35063278
[TBL] [Abstract][Full Text] [Related]
9. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
10. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
11. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
[TBL] [Abstract][Full Text] [Related]
12. PI3K p110α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells.
Lee HJ; Kim KJ; Sung JH; Nam M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Kim JH
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899250
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Azaro A; Massard C; Tap WD; Cassier PA; Merchan J; Italiano A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
Invest New Drugs; 2021 Aug; 39(4):1089-1098. PubMed ID: 33686452
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Zauderer MG; Alley EW; Bendell J; Capelletto E; Bauer TM; Callies S; Szpurka AM; Kang S; Willard MD; Wacheck V; Varghese AM
Invest New Drugs; 2021 Aug; 39(4):1081-1088. PubMed ID: 33660194
[TBL] [Abstract][Full Text] [Related]
16. [ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib].
Terasawa R; Takashima Y; Hirata A; Kimura K; Morita S; Hayashi M
Gan To Kagaku Ryoho; 2023 Aug; 50(8):901-903. PubMed ID: 37608417
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
Wu CP; Hung CY; Lusvarghi S; Huang YH; Tseng PJ; Hung TH; Yu JS; Ambudkar SV
Biochem Pharmacol; 2020 Oct; 180():114137. PubMed ID: 32634436
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Litchfield LM; Boehnke K; Brahmachary M; Mur C; Bi C; Stephens JR; Sauder JM; Gutiérrez SM; McNulty AM; Ye XS; Wu W; Lallena MJ; Gong X; Merzoug FF; Jansen VM; Buchanan SG
Oncotarget; 2020 Apr; 11(17):1478-1492. PubMed ID: 32391118
[TBL] [Abstract][Full Text] [Related]
20. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]